Literature DB >> 25687406

Suppressing TGFβ signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer.

Hiroko Oshima1, Mizuho Nakayama2, Tae-Su Han2, Kuniko Naoi1, Xiaoli Ju1, Yusuke Maeda1, Sylvie Robine3, Kiichiro Tsuchiya4, Toshiro Sato5, Hiroshi Sato6, Makoto Mark Taketo7, Masanobu Oshima8.   

Abstract

Genetic alterations in the TGFβ signaling pathway in combination with oncogenic alterations lead to cancer development in the intestines. However, the mechanisms of TGFβ signaling suppression in malignant progression of intestinal tumors have not yet been fully understood. We have examined Apc(Δ716) Tgfbr2(ΔIEC) compound mutant mice that carry mutations in Apc and Tgfbr2 genes in the intestinal epithelial cells. We found inflammatory microenvironment only in the invasive intestinal adenocarcinomas but not in noninvasive benign polyps of the same mice. We thus treated simple Tgfbr2(ΔIEC) mice with dextran sodium sulfate (DSS) that causes ulcerative colitis. Importantly, these Tgfbr2(ΔIEC) mice developed invasive colon cancer associated with chronic inflammation. We also found that TGFβ signaling is suppressed in human colitis-associated colon cancer cells. In the mouse invasive tumors, macrophages infiltrated and expressed MT1-MMP, causing MMP2 activation. These results suggest that inflammatory microenvironment contributes to submucosal invasion of TGFβ signaling-repressed epithelial cells through activation of MMP2. We further found that regeneration was impaired in Tgfbr2(ΔIEC) mice for intestinal mucosa damaged by DSS treatment or X-ray irradiation, resulting in the expansion of undifferentiated epithelial cell population. Moreover, organoids of intestinal epithelial cells cultured from irradiated Tgfbr2(ΔIEC) mice formed "long crypts" in Matrigel, suggesting acquisition of an invasive phenotype into the extracellular matrix. These results, taken together, indicate that a simple genetic alteration in the TGFβ signaling pathway in the inflamed and regenerating intestinal mucosa can cause invasive intestinal tumors. Such a mechanism may play a role in the colon carcinogenesis associated with inflammatory bowel disease in humans. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25687406     DOI: 10.1158/0008-5472.CAN-14-2036

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection.

Authors:  Ryuma Tokunaga; Yasuo Sakamoto; Shigeki Nakagawa; Daisuke Izumi; Keisuke Kosumi; Katsunobu Taki; Takaaki Higashi; Tatsunori Miyata; Yuji Miyamoto; Naoya Yoshida; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2017-02-17       Impact factor: 3.402

Review 2.  Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.

Authors:  Barbara Jung; Jonas J Staudacher; Daniel Beauchamp
Journal:  Gastroenterology       Date:  2016-10-20       Impact factor: 22.682

Review 3.  TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota.

Authors:  Sozaburo Ihara; Yoshihiro Hirata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2017-05-22       Impact factor: 7.527

4.  Single cell lineage tracing reveals a role for TgfβR2 in intestinal stem cell dynamics and differentiation.

Authors:  Jared M Fischer; Peter P Calabrese; Ashleigh J Miller; Nina M Muñoz; William M Grady; Darryl Shibata; R Michael Liskay
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

5.  Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence.

Authors:  Janusz Franco-Barraza; Ralph Francescone; Tiffany Luong; Neelima Shah; Raj Madhani; Gil Cukierman; Essel Dulaimi; Karthik Devarajan; Brian L Egleston; Emmanuelle Nicolas; R Katherine Alpaugh; Ruchi Malik; Robert G Uzzo; John P Hoffman; Erica A Golemis; Edna Cukierman
Journal:  Elife       Date:  2017-01-31       Impact factor: 8.140

6.  CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes.

Authors:  Haruna Takeda; Shiho Kataoka; Mizuho Nakayama; Mohamed A E Ali; Hiroko Oshima; Daisuke Yamamoto; Jun-Won Park; Yujiro Takegami; Tadaichi An; Nancy A Jenkins; Neal G Copeland; Masanobu Oshima
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-12       Impact factor: 11.205

7.  Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon.

Authors:  K J Baldauf; J M Royal; J C Kouokam; B Haribabu; V R Jala; K Yaddanapudi; K T Hamorsky; G W Dryden; N Matoba
Journal:  Mucosal Immunol       Date:  2016-11-02       Impact factor: 7.313

8.  KIT promotes tumor stroma formation and counteracts tumor-suppressive TGFβ signaling in colorectal cancer.

Authors:  Jamila Laoukili; Onno Kranenburg; Emre Küçükköse; Niek A Peters; Inge Ubink; Veere A M van Keulen; Roxanna Daghighian; André Verheem
Journal:  Cell Death Dis       Date:  2022-07-16       Impact factor: 9.685

9.  Suppression of Membranous LRP5 Recycling, Wnt/β-Catenin Signaling, and Colon Carcinogenesis by 15-LOX-1 Peroxidation of Linoleic Acid in PI3P.

Authors:  Fuyao Liu; Xiangsheng Zuo; Yi Liu; Yasunori Deguchi; Micheline J Moussalli; Weidong Chen; Peiying Yang; Bo Wei; Lin Tan; Philip L Lorenzi; Shen Gao; Jonathan C Jaoude; Amir Mehdizadeh; Lovie Ann Valentin; Daoyan Wei; Imad Shureiqi
Journal:  Cell Rep       Date:  2020-08-18       Impact factor: 9.423

Review 10.  Drug Discovery via Human-Derived Stem Cell Organoids.

Authors:  Fangkun Liu; Jing Huang; Bo Ning; Zhixiong Liu; Shen Chen; Wei Zhao
Journal:  Front Pharmacol       Date:  2016-09-22       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.